Haemonetics Corp
NYSE:HAE

Watchlist Manager
Haemonetics Corp Logo
Haemonetics Corp
NYSE:HAE
Watchlist
Price: 87.89 USD -0.72% Market Closed
Market Cap: 4.4B USD
Have any thoughts about
Haemonetics Corp?
Write Note

Haemonetics Corp
Net Issuance of Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Haemonetics Corp
Net Issuance of Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Debt CAGR 3Y CAGR 5Y CAGR 10Y
Haemonetics Corp
NYSE:HAE
Net Issuance of Debt
$493.5m
CAGR 3-Years
15%
CAGR 5-Years
79%
CAGR 10-Years
N/A
DENTSPLY SIRONA Inc
NASDAQ:XRAY
Net Issuance of Debt
$146m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ICU Medical Inc
NASDAQ:ICUI
Net Issuance of Debt
-$46.8m
CAGR 3-Years
-327%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Align Technology Inc
NASDAQ:ALGN
Net Issuance of Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Lantheus Holdings Inc
NASDAQ:LNTH
Net Issuance of Debt
-$393k
CAGR 3-Years
79%
CAGR 5-Years
65%
CAGR 10-Years
-7%
Merit Medical Systems Inc
NASDAQ:MMSI
Net Issuance of Debt
$454.6m
CAGR 3-Years
N/A
CAGR 5-Years
14%
CAGR 10-Years
N/A
No Stocks Found

Haemonetics Corp
Glance View

Market Cap
4.4B USD
Industry
Health Care

Haemonetics Corp. is a global healthcare company, which engages in the development and distribution of hematology products and solutions. The company is headquartered in Boston, Massachusetts and currently employs 2,708 full-time employees. The firm provides a suite of medical products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Its technology addresses medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. Its segments include Plasma, Blood Center and Hospital. Its Plasma segment offers automated plasma collection and donor management software systems that improve the donor experience at plasma collection centers. Its Blood Center segment offers a range of solutions that improve donor collection centers' ability to acquire blood, filter blood and separate blood components. Its Hospital segment provides the patient care. The company markets and sells its products to biopharmaceutical companies, blood collection groups and independent blood centers, hospitals and hospital service providers, group purchasing organizations and national health organizations.

HAE Intrinsic Value
100.72 USD
Undervaluation 13%
Intrinsic Value
Price

See Also

What is Haemonetics Corp's Net Issuance of Debt?
Net Issuance of Debt
493.5m USD

Based on the financial report for Sep 28, 2024, Haemonetics Corp's Net Issuance of Debt amounts to 493.5m USD.

What is Haemonetics Corp's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 5Y
79%

The average annual Net Issuance of Debt growth rates for Haemonetics Corp have been 15% over the past three years , 79% over the past five years .

Back to Top